2022-04-12 | NDAQ:LQDA | Press release

MORRISVLLE, North Carolina, April 12, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia”) announced the price for an underwritten public offering of 9,803,922 common shares at an offering price public offering of $5.10, for aggregate gross proceeds of approximately $50.0 million, before deduction of subscription discounts and fees and expenses payable by Liquidia. All shares in the offering will be sold by Liquidia. , Liquidia has granted the underwriters a 30-day option to purchase up to an additional 1,470,588 shares of common stock at the public offering price, less underwriting rebates and fees. The offering is expected to close on April 18, 2022, subject to subject to customary closing conditions.

BofA Securities is acting as sole bookrunner for the offering. Needham & Company and BTIG act as lead managers.

The common stock described above is being offered by Liquidia pursuant to its shelf registration statement on Form S-3, including a base prospectus, which was previously filed by Liquidia with the Securities and Exchange Commission (the “SEC ”) on December 16, 2020, and declared effective by the SEC on December 23, 2020. The proposed offering will be made only by means of a written prospectus and a prospectus supplement forming part of the registration statement. . A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. When available, copies of the final prospectus supplement and accompanying offering prospectus may be obtained from BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255, or by email: dg.prospectus_requests@bofa.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, and there will be no sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or territory.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The Company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH markets pharmaceutical products against rare diseases, such as generic injectable treprostinil.

Forward-looking statements

This press release contains forward-looking statements, including, but not limited to, statements relating to Liquidia’s expectations regarding the completion of the tender offer. These statements can be identified by the use of words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “continues,” “estimates,” “predicts,” “projects ,” “forecasts,” and similar expressions. All forward-looking statements are based on current expectations and beliefs as of the date of this release and are subject to risks, uncertainties and assumptions that could cause actual results to differ. differ materially from those discussed or implied by the forward-looking statements, including, but not limited to, the risk that Liquidia may not be able to complete the proposed public offer under the expected conditions or at all, and the other risks identified in Item 1A under the heading “Risk Factors” CloseCurlyDoubleQuote in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed March 17, 2022. demands, Liquidia does not commit ge does not publicly revise or update any forward-looking statements to reflect events or circumstances after the date of this report, or to reflect the occurrence of unforeseen events or circumstances.

Contact information

Media and Investors:

Jason Adair

Senior Vice President, Corporate Development and Strategy

919.328.4400

jason.adair@liquidia.com